418 related articles for article (PubMed ID: 34942138)
1. Safety and efficacy of lower-sodium oxybate in adults with idiopathic hypersomnia: a phase 3, placebo-controlled, double-blind, randomised withdrawal study.
Dauvilliers Y; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Thorpy MJ; Mignot E; Chandler P; Parvataneni R; Black J; Sterkel A; Chen D; Skobieranda F; Bogan RK
Lancet Neurol; 2022 Jan; 21(1):53-65. PubMed ID: 34942138
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety of low-sodium oxybate in an open-label extension period of a placebo-controlled, double-blind, randomized withdrawal study in adults with idiopathic hypersomnia.
Morse AM; Dauvilliers Y; Arnulf I; Thorpy MJ; Foldvary-Schaefer N; Chandler P; Chen A; Hickey L; Black J; Bogan RK
J Clin Sleep Med; 2023 Oct; 19(10):1811-1822. PubMed ID: 37409509
[TBL] [Abstract][Full Text] [Related]
3. Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation.
Plazzi G; Ruoff C; Lecendreux M; Dauvilliers Y; Rosen CL; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
Lancet Child Adolesc Health; 2018 Jul; 2(7):483-494. PubMed ID: 30169321
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of pitolisant in children aged 6 years or older with narcolepsy with or without cataplexy: a double-blind, randomised, placebo-controlled trial.
Dauvilliers Y; Lecendreux M; Lammers GJ; Franco P; Poluektov M; Caussé C; Lecomte I; Lecomte JM; Lehert P; Schwartz JC; Plazzi G
Lancet Neurol; 2023 Apr; 22(4):303-311. PubMed ID: 36931805
[TBL] [Abstract][Full Text] [Related]
5. Calcium, Magnesium, Potassium and Sodium Oxybates (Xywav
Heo YA
CNS Drugs; 2022 May; 36(5):541-549. PubMed ID: 35357671
[TBL] [Abstract][Full Text] [Related]
6. Long-Term Safety and Tolerability During a Clinical Trial and Open-Label Extension of Low-Sodium Oxybate in Participants with Narcolepsy with Cataplexy.
Bogan RK; Foldvary-Schaefer N; Skowronski R; Chen A; Thorpy MJ
CNS Drugs; 2023 Apr; 37(4):323-335. PubMed ID: 36947322
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello R; Fleseriu M; Newell-Price J; Bertagna X; Findling J; Shimatsu A; Gu F; Auchus R; Leelawattana R; Lee EJ; Kim JH; Lacroix A; Laplanche A; O'Connell P; Tauchmanova L; Pedroncelli AM; Biller BMK;
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):748-761. PubMed ID: 32730798
[TBL] [Abstract][Full Text] [Related]
8. Baricitinib in juvenile idiopathic arthritis: an international, phase 3, randomised, double-blind, placebo-controlled, withdrawal, efficacy, and safety trial.
Ramanan AV; Quartier P; Okamoto N; Foeldvari I; Spindler A; Fingerhutová Š; Antón J; Wang Z; Meszaros G; Araújo J; Liao R; Keller S; Brunner HI; Ruperto N; ;
Lancet; 2023 Aug; 402(10401):555-570. PubMed ID: 37423231
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of calcium, magnesium, potassium, and sodium oxybates (lower-sodium oxybate [LXB]; JZP-258) in a placebo-controlled, double-blind, randomized withdrawal study in adults with narcolepsy with cataplexy.
Bogan RK; Thorpy MJ; Dauvilliers Y; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Tang L; Skobieranda F; Šonka K
Sleep; 2021 Mar; 44(3):. PubMed ID: 33184650
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Lower-Sodium Oxybate in an Open-Label Titration Period of a Phase 3 Clinical Study in Adults with Idiopathic Hypersomnia.
Thorpy MJ; Arnulf I; Foldvary-Schaefer N; Morse AM; Šonka K; Chandler P; Hickey L; Chen A; Black J; Sterkel A; Chen D; Bogan RK; Dauvilliers Y
Nat Sci Sleep; 2022; 14():1901-1917. PubMed ID: 36320423
[TBL] [Abstract][Full Text] [Related]
11. Development of a lower-sodium oxybate formulation for the treatment of patients with narcolepsy and idiopathic hypersomnia.
Junnarkar G; Allphin C; Profant J; Steininger TL; Chen C; Zomorodi K; Skowronski R; Black J
Expert Opin Drug Discov; 2022 Feb; 17(2):109-119. PubMed ID: 34818123
[TBL] [Abstract][Full Text] [Related]
12. Update on the treatment of idiopathic hypersomnia: Progress, challenges, and expert opinion.
Arnulf I; Thomas R; Roy A; Dauvilliers Y
Sleep Med Rev; 2023 Jun; 69():101766. PubMed ID: 36921459
[TBL] [Abstract][Full Text] [Related]
13. Changes in Cataplexy Frequency in a Clinical Trial of Lower-Sodium Oxybate with Taper and Discontinuation of Other Anticataplectic Medications.
Dauvilliers Y; Šonka K; Bogan RK; Partinen M; Del Rio Villegas R; Foldvary-Schaefer N; Skowronski R; Chen A; Black J; Skobieranda F; Thorpy MJ
CNS Drugs; 2022 Jun; 36(6):633-647. PubMed ID: 35635687
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled study demonstrates sodium oxybate is effective for the treatment of excessive daytime sleepiness in narcolepsy.
Xyrem International Study Group
J Clin Sleep Med; 2005 Oct; 1(4):391-7. PubMed ID: 17564408
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and maintenance of efficacy of sodium oxybate in the treatment of narcolepsy with cataplexy in pediatric patients.
Lecendreux M; Plazzi G; Dauvilliers Y; Rosen CL; Ruoff C; Black J; Parvataneni R; Guinta D; Wang YG; Mignot E
J Clin Sleep Med; 2022 Sep; 18(9):2217-2227. PubMed ID: 35689598
[TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial.
Zakrzewska JM; Palmer J; Morisset V; Giblin GM; Obermann M; Ettlin DA; Cruccu G; Bendtsen L; Estacion M; Derjean D; Waxman SG; Layton G; Gunn K; Tate S;
Lancet Neurol; 2017 Apr; 16(4):291-300. PubMed ID: 28216232
[TBL] [Abstract][Full Text] [Related]
17. Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
Black J; Houghton WC
Sleep; 2006 Jul; 29(7):939-46. PubMed ID: 16895262
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Treatment of Narcolepsy and Idiopathic Hypersomnia with Low-Sodium Oxybate.
Schneider LD; Morse AM; Strunc MJ; Lee-Iannotti JK; Bogan RK
Nat Sci Sleep; 2023; 15():663-675. PubMed ID: 37621721
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of pitolisant on cataplexy in patients with narcolepsy: a randomised, double-blind, placebo-controlled trial.
Szakacs Z; Dauvilliers Y; Mikhaylov V; Poverennova I; Krylov S; Jankovic S; Sonka K; Lehert P; Lecomte I; Lecomte JM; Schwartz JC;
Lancet Neurol; 2017 Mar; 16(3):200-207. PubMed ID: 28129985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
